Legend Biotech Achieves CARVYKTI Profitability as Sales Surge Past $1.9 Billion
Event summary
- CARVYKTI net sales hit $1.9 billion for full year 2025, up from prior periods.
- Over 10,000 patients treated with CARVYKTI, expanding global availability to 294 sites.
- Company achieved franchise profitability for CARVYKTI in 2025.
- Cash reserves stood at $949 million as of December 31, 2025.
- Advanced pipeline includes first-patient dosing for in vivo candidates and allogeneic CAR-T therapy LUCAR-G39D.
The big picture
Legend Biotech's profitability milestone with CARVYKTI underscores the growing dominance of cell therapies in treating multiple myeloma. The company's strategic focus on expanding commercial reach, particularly in community settings, aligns with broader industry trends toward decentralized cancer care. With a strong cash position and advancing pipeline, Legend Biotech is positioning itself as a key player in the next wave of innovative cell therapy treatments.
What we're watching
- Commercial Scale
- Whether Legend Biotech can sustain CARVYKTI's growth trajectory amid increased competition in the multiple myeloma CAR-T space.
- Pipeline Progress
- The pace at which early-stage cell therapy candidates, particularly LUCAR-G39D, advance through clinical trials and regulatory approvals.
- Operational Efficiency
- How the company's expanded manufacturing capacity will impact production costs and supply chain logistics for CARVYKTI.
Our editorial coverage:
Related topics